BIOMAT Database Logo BIOMAT Database Logo

Hearing impairment during deferoxamine therapy for thalassemia major. 1991

F Argiolu, and G Diana, and A Avignone, and A Cao, and S Di Ninni

UI MeSH Term Description Entries
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D006319 Hearing Loss, Sensorineural Hearing loss resulting from damage to the COCHLEA and the sensorineural elements which lie internally beyond the oval and round windows. These elements include the AUDITORY NERVE and its connections in the BRAINSTEM. Deafness Neurosensory,Deafness, Neurosensory,Deafness, Sensoryneural,Neurosensory Deafness,Sensorineural Hearing Loss,Sensoryneural Deafness,Cochlear Hearing Loss,Hearing Loss, Cochlear,Deafnesses, Neurosensory,Deafnesses, Sensoryneural,Neurosensory Deafnesses,Sensoryneural Deafness,Sensoryneural Deafnesses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D013789 Thalassemia A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. Thalassemias

Related Publications

F Argiolu, and G Diana, and A Avignone, and A Cao, and S Di Ninni
[Thalassemia major: chelating therapy with deferoxamine].
January 1985, Medicina,
F Argiolu, and G Diana, and A Avignone, and A Cao, and S Di Ninni
Deferoxamine in thalassemia major.
January 1995, The New England journal of medicine,
F Argiolu, and G Diana, and A Avignone, and A Cao, and S Di Ninni
Deferoxamine in thalassemia major.
January 1995, The New England journal of medicine,
F Argiolu, and G Diana, and A Avignone, and A Cao, and S Di Ninni
Deferoxamine in thalassemia major.
January 1995, The New England journal of medicine,
F Argiolu, and G Diana, and A Avignone, and A Cao, and S Di Ninni
Vision and hearing during deferoxamine therapy.
August 1990, The Journal of pediatrics,
F Argiolu, and G Diana, and A Avignone, and A Cao, and S Di Ninni
Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
September 2008, Pediatric hematology and oncology,
F Argiolu, and G Diana, and A Avignone, and A Cao, and S Di Ninni
Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
April 1978, The Journal of pediatrics,
F Argiolu, and G Diana, and A Avignone, and A Cao, and S Di Ninni
Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis.
January 2017, Caspian journal of internal medicine,
F Argiolu, and G Diana, and A Avignone, and A Cao, and S Di Ninni
Deferoxamine-induced bone dysplasia in patients with thalassemia major.
March 1991, AJR. American journal of roentgenology,
F Argiolu, and G Diana, and A Avignone, and A Cao, and S Di Ninni
[Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
May 1994, Medicina clinica,
Copied contents to your clipboard!